Merck: Keytruda improves survival in small cell lung cancer.
(CercleFinance.com) - Keytruda more than doubled survival after two years of follow-up in first-line treatment of patients with metastatic non-small cell lung cancer with high levels of PD-L1, Merck said on Wednesday.
The US drugmaker said it plans to present data at the World Conference on Lung Cancer (WCLC) hosted in Yokohama, Japan, which will show a median overall survival of 30 months for Keytruda compared to 14.2 months for chemotherapy.
Keytruda - which reinforces the body's immune system to help detect and fight tumor cells - is currently involved in over 600 trials across a wide variety of cancers.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The US drugmaker said it plans to present data at the World Conference on Lung Cancer (WCLC) hosted in Yokohama, Japan, which will show a median overall survival of 30 months for Keytruda compared to 14.2 months for chemotherapy.
Keytruda - which reinforces the body's immune system to help detect and fight tumor cells - is currently involved in over 600 trials across a wide variety of cancers.
Copyright (c) 2017 CercleFinance.com. All rights reserved.